The food industry inspired single-use in biopharma, but the regulatory landscape is far more complex. If you're worried about compliance, this discussion can help.
- Deploying A Vendor Life Cycle Oversight Model
- Moving Leukopaks From GTP To GMP Is One Cell Therapy Trend To Watch In '26
- Metrics, Not Audits, Should Lead Vendor Accountability
- Ask The Pros — The Latest In Upstream HCP Mitigation
- 2026 CDMO Forecast: The 7 Shifts Sponsors Need To Prepare For
- Biosimilar Manufacturing Complexity Demands Mastery, Not Mimicry
- A Deeper Look At Pharma's Structural Supply Chain Vulnerability
EDITOR'S DESK
-
Supporting The Next Generation Of ADCs
Experts discuss innovation in antibody-drug conjugate (ADC) technology and how these impact CMC strategy. This summary captures key takeaways from the Bioprocess Online Live event "Evolving CMC Strategies To Enable Next-Gen ADCs."
Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.
At BioProcess International 2025, leaders from AbbVie and Amgen gave keynote presentations about how their companies are advancing product development through digital tools.
AI consultant Kat Kozyrytska advocates for ethical AI adoption and explains its potential to foster collaboration across the industry.
Takeda head of process development, Amy Shaw, explains what factors to consider when scaling up or scaling out cell therapy manufacturing.
GUEST COLUMNISTS
-
Deploying A Vendor Life Cycle Oversight Model
A practical guide for adding oversight, based on a hierarchy of metrics, to quality agreements to transform them into living, metrics-driven control instruments.
-
Moving Leukopaks From GTP To GMP Is One Cell Therapy Trend To Watch In '26
Cell therapy stumbled in 2025. Solving the variability in starting material quality is critical to stabilizing manufacturing in 2026.
-
Metrics, Not Audits, Should Lead Vendor Accountability
Episodic vendor audits are better suited for high-risk areas. An oversight system, based on a hierarchy of metrics, provides greater value.
-
Ask The Pros — The Latest In Upstream HCP Mitigation
We asked leading experts how upstream interventions can reshape HCP control. Here’s what they shared. Answers have been edited for clarity.
-
2026 CDMO Forecast: The 7 Shifts Sponsors Need To Prepare For
2026 is shaping up to be a year in which operational discipline, strategic alignment, and regulatory preparedness will differentiate high-performing sponsors from those facing avoidable delays.
-
Biosimilar Manufacturing Complexity Demands Mastery, Not Mimicry
GlycoNex's denosumab biosimilar development experience illustrates how a "just copy it" approach is an insufficient strategy in modern biomanufacturing.
-
A Deeper Look At Pharma's Structural Supply Chain Vulnerability
Fixing limited capacity in pharmaceutical CMC development starts with understanding a complex web of root causes.
-
Survey: SUS Insufficient For 40% Of Biopharma
New data from BioPlan Associates suggests single-use systems adoption may be plateauing with single-digit growth rates.
BIOPROCESSING WHITE PAPERS
-
Achieve Higher Targeted Concentrations
Single-pass TFF streamlines downstream processing by reducing footprint, shear exposure, and hold-up volumes. Learn how this approach is advancing efficiency across therapeutic and vaccine production.
-
Understanding Viral Clearance During Anion-Exchange Chromatography3/26/2024
A design of experiments (DoE) study examined the anion-exchange process in general and to draw possible correlations between such properties and overall viral clearance capability.
-
Accelerating ADC Clinical Development Timelines8/28/2024
For ADC developers, obtaining the desired payload can be a challenge, as their synthesis is more complex than most other small molecules. Learn about a more efficient approach to payload synthesis.
-
The Problem With Construction Quality10/21/2024
Data center construction quality management is inadequate, with issues traced to human error. A stronger focus on quality control and assurance is needed for success.
-
Performance Of HEKima™ Adherent HEK Cell Medium9/16/2024
Explore the performance of a serum-free medium designed for HEK-293 cells, comparing its efficacy to traditional media for protein expression and cell proliferation.
-
Innovation And Evolution Of Affinity Chromatography Resins For Monoclonal Antibody Purification9/30/2025
Discover how innovations in ligand design and resin manufacturing have improved monoclonal antibody purification by enhancing selectivity, stability, and process economics.
BIOPROCESSING APP NOTES & CASE STUDIES
- Maximizing Scale-Up Efficiency Of A mAb Upstream Process
- Multiplex Imaging
- Leveraging Innovative Analytics To Ensure The Thermal Stability Of mAb Drug Products
- Direct Inoculation From Cryopreserved Cell Banks Using An Automated FBR
- Overcoming Scale-Up Challenges In iPSC Production: A Joint Investigation
- Bioprocess Online's 2025 Editorial Reflections
- FDA Releases Draft Guidance To Accelerate Biosimilar Development
- Supporting The Next Generation Of ADCs
- AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing
- On The Ground At BPI: Kat Kozyrytska On Ethical AI And Collaboration
- On The Ground At BPI: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing
- On The Ground At BPI: Industry Reflections With Carl Schoellhammer, Ph.D.
BIOPROCESS ONLINE CONTENT COLLECTIONS
This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 01.13.26 -- 2026 CDMO Forecast: The 7 Shifts Sponsors Need To Prepare For
- 01.12.26 -- Survey: SUS Insufficient For 40% Of Biopharma
- 01.10.26 -- Bioprocess Online Best Of December
- 01.09.26 -- New Podcast Episodes: 2025 Retrospective Of Life Science Industry, Engineering B Cells, Turning Tumor Microenvironment Against Cancer
- 01.09.26 -- The Editors' Roundtable: A 2025 Retrospective Of The Life Science Industry